Polysaccharides as bacterial antiadhesive agents and “smart” constituents for improved drug delivery systems against Helicobacter pylori infection

Current Pharmaceutical Design

Volumn 21, Issue 33, 2015, Pages 4888-4906

  Menchicchi, Bianca ^a   Hensel, Andreas ^a   Goycoolea, Francisco M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Antiadhesion; Antiadhesive therapy; Helicobacter pylori; Polysaccharides

Indexed keywords

AMOXICILLIN; ARABINOGALACTAN; CLARITHROMYCIN; EXOPOLYSACCHARIDE; LEVOFLOXACIN; METRONIDAZOLE; NANOPARTICLE; OLIGOSACCHARIDE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE; POLYSACCHARIDE SULFATE; PROTON PUMP INHIBITOR; RHAMNOGALACTURONAN; TINIDAZOLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BLACK CURRANT; CELL COMMUNICATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; ERADICATION THERAPY; GINSENG; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMAGGLUTINATION; HOST CELL; HUMAN; IN VITRO STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; QUORUM SENSING; REVIEW; TREATMENT DURATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; METABOLISM; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NANOPARTICLES; POLYSACCHARIDES;

EID: 84947997310     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150820104028     Document Type: Review

References (193)

1. Khalifa MM, Sharaf RR, Aziz RK. Helicobacter pylori: a poor man's gut pathogen. Gut Pathog 2010; 2(1): 2.
2. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 2: 33-9.
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52(24): 6735-40.
4. Kuipers EJ, Peña AS, Festen HPM, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 345(8964): 1525-8.
5. Lindholm C, Quiding-Jarbrink M, Lonroth H, Hamlet A, Svennerholm AM. Local cytokine response in Helicobacter pyloriinfected subjects. Infect Immun 1998; 66(12): 5964-71.
6. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19(3): 449- 90.
7. Mishra S. Is Helicobacter pylori good or bad? Eur J Clin Microbiol 2013; 32(3): 301-4.
8. Go MF. What are the host factors that place an individual at risk for Helicobacter pylori-associated disease? Gastroenterology 1997; 113(6, Supplement): S15-S20.
9. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325(16): 1127-31.
10. Moller H, Heseltine E, Vainio H. Working group-report on schistosomes, liver flukes and Helicobacter-pylori. Int J Cancer 1995; 60(5): 587-9.
11. Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1(8336): 1273-5.
12. Montecucco C, Rappuoli R. Living dangerously: How Helicobacter pylori survives in the human stomach. Nat Rev Mol Cell Bio 2001; 2(6): 457-66.
13. Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol 1988; 26(2): 93-9.
14. Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci 1996; 93(25): 14648-53.
15. Leunk R, Johnson P, David B, Kraft W, Morgan D. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol 1988; 26(2): 93-9.
16. Cover TL, Blaser MJ. Helicobacter pylori in Health and Disease. Gastroenterology 2009; 136(6): 1863-73.
17. Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci 1993; 90(12): 5791-5.
18. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55(10): 2111-5.
19. Odenbreit S, Püls J, Sedlmaier B, Gerland E, Fischer W, Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000; 287(5457): 1497-500.
20. Asahi M, Azuma T, Ito S, et al. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000; 191(4): 593-602.
21. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New Engl J Med 1991; 325(16): 1132-6.
22. Crabtree J, Covacci A, Farmery S, et al. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol 1995; 48(1): 41-5.
23. Szabò I, Brutsche S, Tombola F, et al. Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of Helicobacter pylori is required for its biological activity. EMBO J 1999; 18(20): 5517-27.
24. Papini E, De Bernard M, Milia E, et al. Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments. Proc Natl Acad Sci 1994; 91(21): 9720-4.
25. Palframan SL, Kwok T, Gabriel K. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol 2012; 2.
26. Xiang Z, Censini S, Bayeli PF, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immunity 1995; 63(1): 94-8.
27. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the maastricht IV/ florence consensus report. Gut 2012; 61(5): 646-64.
28. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011; 27(6): 565-70
29. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointest Liver 2010; 19(4): 409-14.
30. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104(12): 3069-79.
31. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15(1): 38-45.
32. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003; 18(6): 627-33.
33. Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008; 8(5): 593-7.
34. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005; 100(9): 2083-99.
35. Zullo A, Rinaldi V, Winn S, et al. A new highly effective shortterm therapy schedule for Helicobacter pylori eradication. Aliment Pharm Therap 2000; 14(6): 715-8.
36. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: An update. Eur J Intern Med 2013; 24(1): 16-9.
37. Kanizaj TF, Kunac N. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014; 20(3): 699-705.
38. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000; 63(3): 235-59.
39. Rajinikanth PS, Mishra B. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H. pylori. J Control Release 2008; 125(1): 33-41.
40. Rajinikanth PS, Mishra B. Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm 2007; 57(4): 413-27.
41. Thombre NA, Gide PS. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication. Drug Deliv 2014; 28: 1-15.
42. Lopes D, Nunes C, Martins MCL, Sarmento B, Reis S. Eradication of Helicobacter pylori: Past, present and future. J Control Release 2014; 189: 169-86.
43. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 2013; 65(13-14): 1803-15.
44. Amin M, Anwar F, Janjua MR, Iqbal MA, Rashid U. Green Synthesis of Silver Nanoparticles through Reduction with Solanum xanthocarpum L. Berry Extract: Characterization, Antimicrobial and Urease Inhibitory Activities against Helicobacter pylori. Int J Mol Sci 2012; 13(8): 9923-41.
45. Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence 2012; 3(3): 271-9.
46. Hajipour MJ, Fromm KM, Akbar Ashkarran A, et al. Antibacterial properties of nanoparticles. Trends Biotechnol 2012; 30(10): 499- 511.
47. Friedman A, Blecher K, Sanchez D, et al. Susceptibility of Grampositive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence 2011; 2(3): 217-21.
48. Privett BJ, Broadnax AD, Bauman SJ, Riccio DA, Schoenfisch MH. Examination of bacterial resistance to exogenous nitric oxide. Nitric Oxide 2012; 26(3): 169-73.
49. Menchicchi B, Fuenzalida JP, Hensel A, et al. Biophysical analysis of the molecular interactions between polysaccharides and mucin. Biomacromolecules 2015; 16(3): 924-35.
50. Goycoolea FM, Lollo G, Remunan-Lopez C, Quaglia F, Alonso MJ. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules 2009; 10(7): 1736-43.
51. Prego C, Torres D, Alonso MJ. Chitosan nanocapsules: a new carrier for nasal peptide delivery. J Drug Deliv Sci Technol 2006; 16(5): 331-7.
52. Narkar M, Sher P, Pawar A. Stomach-specific controlled release gellan beads of acid-soluble drug prepared by ionotropic gelation method. AAPS PharmSciTech 2010; 11(1): 267-77.
53. Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol 1999; 51(6): 667- 72.
54. Jain SK, Jangdey MS. Lectin conjugated gastroretentive multiparticulate delivery system of clarithromycin for the effective treatment of Helicobacter pylori. Mol Pharm 2009; 6(1): 295-304.
55. Nagahara N, Akiyama Y, Nakao M, Tada M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother 1998; 42(10): 2492-4.
56. Hu LT, Mobley HLT. Purification and N-terminal analysis of urease from Helicobacter-pylori. Infect Immun 1990; 58(4): 992-8.
57. Brady CE, Hadfield TL, Hyatt JR, Utts SJ. Campylobacter pyloridis - survival in a hostile environment. Am J Gastroenterol 1986; 81(9): 855.
58. Celli JP, Turner BS, Afdhal NH, et al. Rheology of gastric mucin exhibits a pH-dependent sol-gel transition. Biomacromolecules 2007; 8(5): 1580-6.
59. Celli JP, Turner BS, Afdhal NH, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. P Natl Acad Sci USA 2009; 106(34): 14321-6.
60. Lichtenberger LM. The Hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995; 57: 565-83.
61. Goggin PM, Marrero JM, Spychal RT, Jackson PA, Corbishley CM, Northfield TC. Surface hydrophobicity of gastric-mucosa in Helicobacter-pylori infection - effect of clearance and eradication. Gastroenterology 1992; 103(5): 1486-90.
62. Nardone G, Darmiento F, Corso G, Coscione P, Esposito M, Budillon G. Lipids of Human Gastric-Mucosa - Effect of Helicobacter-Pylori Infection and Nonalcoholic Cirrhosis. Gastroenterology 1994; 107(2): 362-8.
63. Hills BA. Gastric-mucosal barrier - evidence for Helicobacterpylori ingesting gastric surfactant and deriving protection from it. Gut 1993; 34(5): 588-93.
64. Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonization of gnotobiotic piglets by Helicobacter-pylori. J Med Microbiol 1992; 37(2): 123-7.
65. Eaton KA, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter-pylori in gnotobiotic piglets. Infect Immun 1991; 59(7): 2470-5.
66. Dorrell N, Martino MC, Stabler RA, et al. Characterization of Helicobacter pylori PldA, a phospholipase with a role in colonization of the gastric mucosa. Gastroenterology 1999; 117(5): 1098-104.
67. An YH, Friedman RJ. Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res 1998; 43(3): 338-48.
68. Katsikogianni M, Missirlis YF. Concise review of mechanisms of bacterial adhesion to biomaterials and of techniques used in estimating bacteria-material interactions. Eur Cell Mater 2004; 8: 37-57.
69. Boks NP, Norde W, van der Mei HC, Busscher HJ. Forces involved in bacterial adhesion to hydrophilic and hydrophobic surfaces. Microbiology 2008; 154(Pt 10): 3122-33.
70. Verwey EJW. Theory of the stability of lyophobic colloids. J Phys Colloid Chem 1947; 51(3): 631-6.
71. Dean PM. Molecular Foundations of Drug-Receptor Interaction. London & Cambridge: Cambridge University Press 1987.
72. Abraham SN, Bishop BL, Sharon N, Ofek I. Chapter 3 - Adhesion of bacteria to mucosal surfaces. In: Strober JMELRMBM, Ed. Mucosal Immunology (Third Edition). Burlington: Academic Press; 2005; pp. 35-48.
73. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279(5349): 373-7.
74. Mahdavi J, Sonden B, Hurtig M, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297(5581): 573-8.
75. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19(3): 449.
76. Van de Bovenkamp JH, Mahdavi J, Korteland-Van Male AM, et al. The MUC5AC glycoprotein is the primary receptor for Helicobacter pylori in the human stomach. Helicobacter 2003; 8(5): 521-32.
77. Walz A, Odenbreit S, Mahdavi J, Boren T, Ruhl S. Identification and characterization of binding properties of Helicobacter pylori by glycoconjugate arrays. Glycobiology 2005; 15(7): 700-8.
78. Aspholm M, Olfat FO, Norden J, et al. SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. Plos Pathog 2006; 2(10): 989-1001.
79. Ascencio F, Fransson LA, Wadstrom T. Affinity of the gastric pathogen Helicobacter-pylori for the N-sulfated glycosaminoglycan heparan-sulfate. J Med Microbiol 1993; 38(4): 240-4.
80. Ruiz-Bustos E, Ochoa JL, Wadstrom T, Ascencio F. Isolation and characterisation of putative adhesins from Helicobacter pylori with affinity for heparan sulphate proteoglycan. J Med Microbiol 2001; 50(3): 215-22.
81. Utt M, Wadstrom T. Identification of heparan sulphate binding surface proteins of Helicobacter pylori: Inhibition of heparan sulphate binding with sulphated carbohydrate polymers. J Med Microbiol 1997; 46(7): 541-6.
82. Ascencio F, Hansson HA, Larm O, Wadstrom T. Helicobacterpylori interacts with heparin and heparin-dependent growth-factors. Fems Immunol Med Mic 1995; 12(3-4): 265-72.
83. Dubreuil JD, Del Giudice G, Rappuoli R. Helicobacter pylori interactions with host serum and extracellular matrix proteins: Potential role in the infectious process. Microbiol Mol Biol R 2002; 66(4): 617.
84. Kamisago S, Iwamori M, Tai T, Mitamura K, Yazaki Y, Sugano K. Role of sulfatides in adhesion of Helicobacter pylori to gastric cancer cells. Infect Immun 1996; 64(2): 624-8.
85. Namavar F, Sparrius M, Veerman ECI, Appelmelk BJ, Vandenbroucke-Grauls CMJE. Neutrophil-activating protein mediates adhesion of Helicobacter pylori to sulfated carbohydrates on high-molecular-weight salivary mucin. Infect Immun 1998; 66(2): 444-7.
86. Lingwood CA, Huesca M, Kuksis A. The Glycerolipid Receptor for Helicobacter-Pylori (and Exoenzyme-S) Is Phosphatidylethanolamine. Infect Immun 1992; 60(6): 2470-4.
87. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19(3): 449- 90.
88. Ofek I, Beachey EH, Sharon N. Surface Sugars of Animal-Cells as Determinants of Recognition in Bacterial Adherence. Trends Biochem Sci 1978; 3(7): 159-60.
89. Ofek I, Mirelman D, Sharon N. Adherence of Escherichia-Coli to Human Mucosal Cells Mediated by Mannose Receptors. Nature 1977; 265(5595): 623-5.
90. Aronson M, Medalia O, Schori L, Mirelman D, Sharon N, Ofek I. Prevention of colonization of the urinary-tract of mice with Escherichia-coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside. J Infect Dis 1979; 139(3): 329-32.
91. Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter-pylori to human gastric epithelium mediated by blood-group antigens. Science 1993; 262(5141): 1892-5.
92. Hirmo S, Kelm S, Iwersen M, et al. Inhibition of Helicobacter pylori sialic acid-specific haemagglutination by human gastrointestinal mucins and milk glycoproteins. FEMS Immunol Med Mic 1998; 20(4): 275-81.
93. Falk P, Roth KA, Boren T, Westblom TU, Gordon JI, Normark S. An in vitro adherence assay reveals that Helicobacter-pylori exhibits cell lineage-specific tropism in the human gastric epithelium. Proc Natl Acad Sci USA 1993; 90(5): 2035-9.
94. Kawakubo M, Ito Y, Okimura Y, et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305(5686): 1003-6.
95. Ofek I, Hasy DL, Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Mic 2003; 38(3): 181-91.
96. Zopf D, Roth S. Oligosaccharide anti-infective agents. Lancet 1996; 347(9007): 1017-21.
97. Ofek I, Kahane I, Sharon N. Toward anti-adhesion therapy for microbial diseases. Trends Microbiol 1996; 4(8): 297-9.
98. Simon PM, Goode PL, Mobasseri A, Zopf D. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect Immun 1997; 65(2): 750-7.
99. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type-1 fimbriated Escherichia-coli to yeast and intestinal epithelial-cells. Infect Immun 1987; 55(2): 472-6.
100. Pieters RJ. Intervention with bacterial adhesion by multivalent carbohydrates. Med Res Rev 2007; 27(6): 796-816.
101. Sigal GB, Mammen M, Dahmann G, Whitesides GM. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J Am Chem Soc 1996; 118(16): 3789-800.
102. Spevak W, Nagy JO, Charych DH, Schaefer ME, Gilbert JH, Bednarski MD. Polymerized liposomes containing C-glycosides of sialic acid: potent inhibitors of influenza virus in vitro infectivity. J Am Chem Soc 1993; 115(3): 1146-7.
103. Nogueira F, Goncalves IC, Martins MCL. Effect of gastric environment on Helicobacter pylori adhesion to a mucoadhesive polymer. Acta Biomater 2013; 9(2): 5208-15.
104. Parreira P, Magalhaes A, Goncalves IC, et al. Effect of surface chemistry on bacterial adhesion, viability, and morphology. J Biomed Mater Res A 2011; 99A(3): 344-53.
105. Jain P, Jain S, Prasad KN, Jain SK, Vyas SP. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of helicobacter pylori infection. Mol Pharmaceut 2009; 6(2): 593-603.
106. Evans DG, Evans DJ, Moulds JJ, Graham DY. NAcetylneuraminyllactose- binding fibrillar hemagglutinin of campylobacter-pylori - a putative colonization factor antigen. Infect Immun 1988; 56(11): 2896-906.
107. Mysore JV, Wigginton T, Simon PM, Zopf D, Heman-Ackah LM, Dubois A. Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound. Gastroenterology 1999; 117(6): 1316-25.
108. Parente F, Cucino C, Anderloni A, Grandinetti G, Porro GB. Treatment of helicobacter pylori infection using a novel antiadhesion compound (3 ' sialyllactose sodium salt). A double blind, placebo-controlled clinical. Helicobacter 2003; 8(4): 252-6.
109. Kojima N, Seino K, Sato Y, Mizuochi T. Carbohydrate carriers affect adhesion of H-pylori to immobilized Le(b)-oligosaccharide. FEBS Lett 2002; 517(1-3): 32-6.
110. Gustafsson A, Hultberg A, Sjostrom R, et al. Carbohydratedependent inhibition of Helicobacter pylori colonization using porcine milk. Glycobiology 2006; 16(1): 1-10.
111. Ramberg JE, Nelson ED, Sinnott RA. Immunomodulatory dietary polysaccharides: a systematic review of the literature. Nutr J 2010; 9(54): 1475-2891.
112. Rostand KS, Esko JD. Microbial adherence to and invasion through proteoglycans. Infect Immun 1997; 65(1): 1-8.
113. Lengsfeld C, Titgemeyer F, Faller G, Hensel A. Glycosylated compounds from okra inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Agric Food Chem 2004; 52(6): 1495-503.
114. Sengkhamparn N, Bakx EJ, Verhoef R, Schols HA, Sajjaanantakul T, Voragen AGJ. Okra pectin contains an unusual substitution of its rhamnosyl residues with acetyl and alpha-linked galactosyl groups. Carbohydr Res 2009; 344(14): 1842-51.
115. Messing J, Thole C, Niehues M, et al. Antiadhesive properties of abelmoschus esculentus (Okra) immature Fruit extract against Helicobacter pylori adhesion. Plos One 2014; 9(1).
116. Niehues M, Euler M, Georgi G, Mank M, Stahl B, Hensel A. Peptides from Pisum sativum L. enzymatic protein digest with antiadhesive activity against Helicobacter pylori: structure-activity and inhibitory activity against BabA, SabA, HpaA and a fibronectinbinding adhesin. Mol Nutr Food Res 2010; 54(12): 1851-61.
117. Lengsfeld C, Faller G, Hensel A. Okra polysaccharides inhibit adhesion of Campylobacter jejuni to mucosa isolated from poultry in vitro but not in vivo. Anim Feed Sci Tech 2007; 135(1-2): 113- 25.
118. Sharon N, Ofek I. Safe as mother's milk: carbohydrates as future anti-adhesion drugs for bacterial diseases. Glycoconj J 2000; 17(7- 9): 659-64.
119. Messing J, Niehues M, Shevtsova A, Boren T, Hensel A. Antiadhesive properties of arabinogalactan protein from ribes nigrum seeds against bacterial adhesion of Helicobacter pylori. Molecules 2014; 19(3): 3696-717.
120. Lengsfeld C, Deters A, Faller G, Hensel A. High molecular weight polysaccharides from black currant seeds inhibit adhesion of Helicobacter pylori to human gastric mucosa. Planta Med 2004; 70(7): 620-6.
121. Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from Liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol 2009; 125(2): 218-23.
122. Krausse R, Bielenberg J, Blaschek W, Ullmann U. In vitro anti- Helicobacter pylori activity of Extractum liquiritiae, glycyrrhizin and its metabolites. J Antimicrob Chemoth 2004; 54(1): 243-6.
123. Sun XB, Matsumoto T, Yamada H. Anti-ulcer activity and mode of action of the polysaccharide fraction from the leaves of Panax ginseng. Planta Med 1992; 58(5): 432-5.
124. Xiao-Bo S, Tsukasa M, Hiroaki K, Masumi H, Haruki Y. Cytoprotective activity of pectic polysaccharides from the root of Panax ginseng. J Ethnopharmacol 1991; 31(1): 101-7.
125. Belogortseva NI, Yoon JY, Kim KH. Inhibition of Helicobacter pylori hemagglutination by polysaccharide fractions from roots of Panax ginseng. Planta Medica 2000; 66(3): 217-20.
126. Woo JS, Ha BH, Kim TG, Lim YH, Kim KH. Development of an enzyme-linked glycosorbent method to monitor the inhibition of sialic acid-dependent Helicobacter pylori adhesion. Biotechnol Lett 2001; 23(7): 507-11.
127. Xu C, Ruan XM, Li HS, et al. Anti-adhesive effect of an acidic polysaccharide from Aloe vera L. var. chinensis (Haw.) Berger on the binding of Helicobacter pylori to the MKN-45 cell line. J Pharm Pharmacol 2010; 62(12): 1753-9.
128. Lee JH, Park EK, Uhm CS, Chung MS, Kim KH. Inhibition of Helicobacter pylori adhesion to human gastric adenocarcinoma epithelial cells by acidic polysaccharides from Artemisia capillaris and Panax ginseng. Planta Medica 2004; 70(7): 615-9.
129. Lee JH, Shim JS, Lee JS, Kim MK, Chung MS, Kim KH. Pectinlike acidic polysaccharide from Panax ginseng with selective antiadhesive activity against pathogenic bacteria. Carbohydr Res 2006; 341(9): 1154-63.
130. Marcial G, Sendker J, Brandt S, et al. Gastroprotection as an example: Antiadhesion against Helicobacter pylori, antiinflammatory and antioxidant activities of aqueous extracts from the aerial parts of Lippia integrifolia Hieron. J Ethnopharmacol 2014; 155(2): 1125-33.
131. Burger O, Ofek I, Tabak M, Weiss EI, Sharon N, Neeman I. A high molecular mass constituent of cranberry juice inhibits Helicobacter pylori adhesion to human gastric mucus. FEMS Immunol Med Mic 2000; 29(4): 295-301.
132. Shmuely H, Burger O, Neeman I, et al. Susceptibility of Helicobacter pylori isolates to the antiadhesion activity of a highmolecular- weight constituent of cranberry. Diagn Micr Infec Dis 2004; 50(4): 231-5.
133. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2012(10).
134. Gotteland M, Andrews M, Toledo M, et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children. Nutrition 2008; 24(5): 421- 6.
135. Zhang L, Ma JL, Pan KF, Go VLW, Chen JS, You WC. Efficacy of cranberry juice on Helicobacter pylori infection: A double-blind, randomized placebo-controlled trial. Helicobacter 2005; 10(2): 139- 45.
136. Ofek I, Goldhar J, Zafriri D, Lis H, Adar R, Sharon N. Anti- Escherichia coli adhesin activity of cranberry and blueberry juices. N Engl J Med 1991; 324(22): 1599.
137. Matsushima M, Suzuki T, Masui A, et al. Growth inhibitory action of cranberry on Helicobacter pylori. J Gastroen Hepatol 2008; 23: S175-S80.
138. Popov SV, Markov PA, Nikitina IR, Petrishev S, Smirnov V, Ovodov YS. Preventive effect of a pectic polysaccharide of the common cranberry Vaccinium oxycoccos L. on acetic acid-induced colitis in mice. World J Gastroenterol 2006; 12(41): 6646-51.
139. Hotchkiss AT, Nunez A, Khoo C, STRAHAN GD. Cranberry xyloglucan oligosaccharide composition. Google Patents 2013.
140. Hirmo S, Utt M, Ringner M, Wadstrom T. Inhibition of heparansulfate and other glycosaminoglycans binding to helicobacterpylori by various polysulfated carbohydrates. FEMS Immunol Med Mic 1995; 10(3-4): 301-6.
141. Ricketts CR. Dextran sulphate-a synthetic analogue of heparin. Biochem J 1952; 51(1): 129-33.
142. Patankar MS, Oehninger S, Barnett T, Williams RL, Clark GF. A Revised Structure for Fucoidan May Explain Some of Its Biological-Activities. J Biol Chem 1993; 268(29): 21770-6.
143. Song W, Wang Y, Zhang L, Fu S, Zeng Y, Hu H. Preparation and evaluation of polysaccharide sulfates for inhibiting Helicobacter pylori adhesion. Carbohydr Polym 2014; 103: 398-404.
144. Guzman-Murillo MA, Ruiz-Bustos E, Ho B, Ascencio F. Involvement of the heparan sulphate-binding proteins of Helicobacter pylori in its adherence to HeLa S3 and Kato III cell lines. J Med Microbiol 2001; 50(4): 320-9.
145. Wadstrom T, Hirmo S, Novak H, et al. Sulfatides inhibit binding of Helicobacter pylori to the gastric cancer Kato III cell line. Curr Microbiol 1997; 34(5): 267-72.
146. Chmiela M, Czkwianianc E, Wadstrom T, Rudnicka W. Role of Helicobacter pylori surface structures in bacterial interaction with macrophages. Gut 1997; 40(1): 20-4.
147. Guzman-Murillo MA, Ascencio F. Anti-adhesive activity of sulphated exopolysaccharides of microalgae on attachment of red sore disease-associated bacteria and Helicobacter pylori to tissue culture cells. Lett Appl Microbiol 2000; 30(6): 473-8.
148. Loke MF, Lui SY, Ng BL, Gong M, Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Mic 2007; 50(2): 231-8.
149. Icatlo FC, Kuroki M, Kobayashi C, et al. Affinity purification of Helicobacter pylori urease - Relevance to gastric mucin adherence by urease protein. J Biol Chem 1998; 273(29): 18130-8.
150. Icatlo FC, Goshima H, Kimura N, Kodama Y. Acid-dependent adherence of Helicobacter pylori urease to diverse polysaccharides. Gastroenterology 2000; 119(2): 358-67.
151. Shibata H, Iimuro M, Uchiya N, et al. Preventive effects of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2003; 8(1): 59-65.
152. Araki Y, Andoh A, Fujiyama Y, Bamba T. Development of dextran sulphate sodium-induced experimental colitis is suppressed in genetically mast cell-deficient Ws/Ws rats. Clin Exp Immunol 2000; 119(2): 264-9.
153. Shibata H, Kimura-Takagi I, Nagaoka M, et al. Inhibitory effect of Cladosiphon fucoidan on the adhesion of Helicobacter pylori to human gastric cells. J Nutr Sci Vitaminol 1999; 45(3): 325-36.
154. Matsumoto S, Nagaoka M, Hara T, Kimura-Takagi I, Mistuyama K, Ueyama S. Fucoidan derived from Cladosiphon okamuranus Tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells. Clin Exp Immunol 2004; 136(3): 432-9.
155. Lutay N, Nilsson I, Wadstrom T, Ljungh A. Effect of heparin, fucoidan and other polysaccharides on adhesion of enterohepatic helicobacter species to murine macrophages. Appl Biochem Biotech 2011; 164(1): 1-9.
156. Welman AD, Maddox IS. Exopolysaccharides from lactic acid bacteria: perspectives and challenges. Trends Biotechnol 2003; 21(6): 269-74.
157. Marcial G, Messing J, Menchicchi B, et al. Effects of polysaccharide isolated from Streptococcus thermophilus CRL1190 on human gastric epithelial cells. Int J Biol Macromol 2013; 62: 217-24.
158. Ascenio F, Gama NL, De Philippis R, Ho B. Effectiveness of Cyanothece spp. and cyanospira capsulata exocellular polysaccharides as antiadhesive agents for blocking attachment of Helicobacter pylori to human gastric cells. Folia Microbiol 2004; 49(1): 64-70.
159. Patel JK, Patel MM. Stomach specific anti-helicobacter pylori therapy: preparation and evaluation of amoxicillin-loaded chitosan mucoadhesive microspheres. Curr Drug Deliv 2007; 4(1): 41-50.
160. Patel J, Patil P. Preparation and characterization of amoxicillin mucoadhesive microparticles using solution-enhanced dispersion by supercritical CO(2). J Microencapsul 2012; 29(4): 398-408.
161. Fuenzalida JP, Weikert T, Hoffmann S, et al. Affinity protein-based FRET tools for cellular tracking of chitosan nanoparticles and determination of the polymer degree of acetylation. Biomacromolecules 2014; 15(7): 2532-9.
162. Mammen M, Dahmann G, Whitesides GM. Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. J Med Chem 1995; 38(21): 4179-90.
163. Nicholson KG, Webster RG, Hay AJ. In: Nicholson KG, Webster RG, Hay AJ, editor. Textbook of influenza. Oxford: Blackwell Science 1998. pp. 29-42.
164. Kingery-Wood JE, Williams KW, Sigal GB, Whitesides GM. The agglutination of erythrocytes by influenza virus is strongly inhibited by liposomes incorporating an analog of sialyl gangliosides. J Am Chem Soc 1992; 114(18): 7303-5.
165. Goncalves IC, Magalhaes A, Fernandes M, Rodrigues IV, Reis CA, Martins MCL. Bacterial-binding chitosan microspheres for gastric infection treatment and prevention. Acta Biomater 2013; 9(12): 9370-8.
166. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998; 43(Suppl 1): S56-S60.
167. Rafsanjany N, Lechtenberg M, Petereit F, Hensel A. Antiadhesion as a functional concept for protection against uropathogenic Escherichia coli: in vitro studies with traditionally used plants with antiadhesive activity against uropathognic Escherichia coli. J Ethnopharmacol 2013; 145(2): 591-7.
168. Leckband DE, Schmitt FJ, Israelachvili JN, Knoll W. Direct Force Measurements of Specific and Nonspecific Protein Interactions. Biochemistry 1994; 33(15): 4611-24.
169. Israelachvili JN. Hydrocolloids Part I. In: Amsterdam: Nishinari K, Ed., Elsevier Science 2000.
170. Umamaheshwari RB, Jain NK. Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. J Control Release 2004; 99(1): 27-40.
171. Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. Genipincross- linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 2013; 34(18): 4466-79.
172. Jain AK, Jain SK. Development and characterization of nanolipobeads-based dual drug delivery system for H. pylori targeting. J Drug Target 2013; 21(6): 593-603.
173. Basque JR, Chenard M, Chailler P, Menard D. Gastric cancer cell lines as models to study human digestive functions. J Cell Biochem 2001; 81(2): 241-51.
174. Osaki T, Yamaguchi H, Taguchi H, Kumada J, Ogata S, Kamiya S. Studies on the relationship between adhesive activity and haemagglutination by Helicobacter pylori. J Med Microbiol 1997; 46(2): 117-21.
175. Dytoc M, Gold B, Louie M, et al. Comparison of helicobacterpylori and attaching-effacing Escherichia-coli adhesion to eukaryotic cells. Infection Immunity 1993; 61(2): 448-56.
176. Sgouras DN, Panayotopoulou E, Martinez-Gonzalez B, Petraki K, Michopoulos S, Mentis A. Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces the levels of proinflammatory cytokines in the gastric epithelium of C57BL/6 mice. Helicobacter 2005; 10(5): 491.
177. Pantoflickova D, Corthesy-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003; 18(8): 805-13.
178. Inngjerdingen KT, Thole C, Diallo D, Paulsen BS, Hensel A. Inhibition of Helicobacter pylori adhesion to human gastric adenocarcinoma epithelial cells by aqueous extracts and pectic polysaccharides from the roots of Cochlospermum tinctorium A. Rich. and Vernonia kotschyana Sch. Bip. ex Walp. Fitoterapia 2014; 95: 127-32.
179. Tvete Inngjerdingen K, Ballo Ng, Zhang BZ, et al. A comparison of bioactive aqueous extracts and polysaccharide fractions from roots of wild and cultivated Cochlospermum tinctorium A. Rich. Phytochemistry 2013; 93(0): 136-43.
180. Patankar MS, Oehninger S, Barnett T, Williams RL, Clark GF. A revised structure for fucoidan may explain some of its biological activities. J Biol Chem 1993; 268(29): 21770-6.
181. Nagaoka M, Shibata H, Kimura-Takagi I, et al. Structural study of fucoidan from Cladosiphon okamuranus TOKIDA. Glycoconj J 1999; 16(1): 19-26.
182. Beil W, Kilian P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine 2007; 6: 5-8.
183. Ascencio F, Gama NL, De Philippis R, Ho B. Effectiveness of Cyanothece spp. and Cyanospira capsulata exocellular polysaccharides as antiadhesive agents for blocking attachment of Helicobacter pylori to human gastric cells. Folia Microbiol 2004; 49(1): 64-70.
184. Clyne M, Drumm B. Absence of effect of Lewis A and Lewis B expression on adherence of Helicobacter pylori to human gastric cells. Gastroenterology 1997; 113(1): 72-80.
185. Odenbreit S, Till M, Hofreuter D, Faller G, Haas R. Genetic and functional characterization of the alpAB gene locus essential for the adhesion of Helicobacter pylori to human gastric tissue. Mol Microbiol 1999; 31(5): 1537-48.
186. Ismaili A, Philpott DJ, Dytoc MT, Soni R, Ratnam S, Sherman PM. Alpha-actinin accumulation in epithelial cells infected with attaching and effacing gastrointestinal pathogens. J Infect Dis 1995; 172(5): 1393-6.
187. Wadstrom T, Hirmo S, Novak H, et al. Sulfatides inhibit binding of Helicobacter pylori to the gastric cancer Kato III cell line. Curr Microbiol 1997; 34(5): 267-72.
188. Neman-Simha V, Mégraud F. In vitro model for Campylobacter pylori adherence properties. Infect Immun 1988; 56(12): 3329-33.
189. Corthésy-Theulaz I, Porta N, Pringault E, et al. Adhesion of Helicobacter pylori to polarized T84 human intestinal cell monolayers is pH dependent. Infect Immun 1996; 64(9): 3827-32.
190. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997; 112(4): 1386-97.
191. van Doorn NE, Namavar F, Sparrius M, et al. Helicobacter pyloriassociated gastritis in mice is host and strain specific. Infect Immun 1999; 67(6): 3040-6.
192. Hirmo S, Kelm S, Schauer R, Nilsson B, Wadstrom T. Adhesion of Helicobacter pylori strains to alpha-2,3-linked sialic acids. Glycoconj J 1996; 13(6): 1005-11.
193. Smoot DT, Resau JH, Naab T, et al. Adherence of Helicobacter pylori to cultured human gastric epithelial cells. Infection Immunity 1993; 61(1): 350-5.